Business Wire

25 Disruptive Technology Startups Join Morgan Stanley Inclusive Ventures Lab’s 10th Cohort

Share

Tenth Lab cohort includes 25 disruptive technology and technology-enabled startups from the Americas and EMEA Five-month accelerator program to provide founders with $250,000 (£250,000) investment, as well as mentorship and business-growth resources 117 companies have participated in the Lab to date

Morgan Stanley (NYSE: MS) today announced the 2024 global cohort of the Inclusive Ventures Lab, with 25 companies selected from the Americas and Europe, the Middle East and Africa (EMEA). Over the next five months, the companies will participate in an in-house accelerator program designed to further develop and scale technology and technology-enabled startups in the seed to Series A funding round stage.

Chosen from thousands of applications, the 25 startups represent a range of disruptive technologies across industries such as Climate Tech, Retail, Healthcare, FinTech, SaaS, Enterprise Software, Consumer and Travel – with many incorporating AI and sustainability into their products and services. Cohort companies will receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities, a tailored entrepreneurship curriculum and business-growth resources from the firm’s ecosystem of internal and external partners.

“In today’s challenging venture capital environment, we are proud to welcome our largest cohort of groundbreaking startups to the Inclusive Ventures Lab and are eager to support them as they scale their innovations and work to build a better world,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “Each year since the Inclusive Ventures Lab’s launch in 2017, we have expanded our efforts to ensure that more entrepreneurs around the world can succeed – and this year is no different.”

The companies selected to participate in the 2024 cohort include the following:

  • Agri-Trak digitizes small farm operations with a smart platform for real-time labor, crop yield and cost tracking to optimize productivity, sustainability and profitability (US)
  • Beta Financial provides a transparent and comprehensive small business credit scoring solution, fostering financial inclusion and access to capital through innovative AI-driven technology (US)
  • Blip Energy is building a drop-in distributed energy resource to mitigate surging peak demand, optimize energy costs for users and reduce operating costs for utilities (US)
  • Compare Ethics is an AI-powered sustainability compliance platform that reduces costs by helping retail brands simplify, streamline and scale the way they make accurate green claims (UK)
  • Darent is a vacation rental marketplace platform in Saudi Arabia for travelers to search for properties with a focus on local experiences, a secure payment system and property insurance for hosts (Saudi Arabia)
  • For The Creators is an omni-channel circular fashion marketplace where women can rent and buy high-quality clothing for each stage of motherhood (UK)
  • GroceryList is a marketplace connecting immigrants worldwide with local merchants across Latin America and the Caribbean, enabling them to purchase groceries and essentials for their loved ones back home (US)
  • HANX is a consumer platform bringing together medically designed women’s reproductive health products, prescription treatments and community-focused content (UK)
  • Hire Ground is a B2B software platform that enables enterprise buyers to source and manage third party vendors while optimizing their procurement process (US)
  • Infinite Giving is a fintech platform that enables nonprofits to raise money, manage their cash reserves, and conservatively invest and grow (US)
  • Juniver is a health company leveraging AI technology to provide personalized digital interventions for lasting eating disorder recovery (UK)
  • KSI Vision uses existing AI on store and shopping center security cameras to generate real-time customer data and increase sales conversion (Uruguay)
  • Mavity is an AI-powered operating system for design and marketing teams that connects companies with on-demand creatives to streamline asset creation (US)
  • MyARC is a platform that enables fitness content creators to train their fans at scale (UK)
  • NÜWIEL provides electric mobility solutions for the cities of today and tomorrow (Germany)
  • OVUM is a one-stop shop for fertility wellness, providing educational resources, products and services for improving fertility outcomes (UK)
  • Research Grid is an automation engine for admin-free clinical trials (UK)
  • Revere is reinventing how allocators manage their alternative asset portfolios through AI, workflow automation tools and custom reporting (US)
  • Route is a platform of business management tools for commercial cleaning companies to automate sales, streamline operations, build contractor relationships and connect the entire cleaning industry (US)
  • Sanarai connects the Latino community to mental health professionals in Latin America and the US to offer culturally sensitive, Spanish-language emotional support at accessible prices (US)
  • Soralink leverages AI and smart sensors to assist manufacturers in preventing critical machine failures (Canada)
  • Sortile provides the textile industry with a system that enables the identification, traceability and recycling of textiles (US)
  • SWYE360 Learning is a data analytics company that uses machine learning and AI in education to measure software efficacy and detect students at risk of dropping out (US)
  • Tendo Technologies addresses the challenges faced by aspiring online retail entrepreneurs in Africa by connecting independent resellers to suppliers (Ghana)
  • Zest Equity is digitizing private market transactions, building tools to streamline and ensure greater transparency in how entrepreneurs, funds and investors transact (UAE)

Programming will culminate in February 2025 with a global Demo Day, when participating companies will present to potential investors, business partners and customers. The investment firms in attendance at the last showcase represented over $40 billion of dry powder and indicated a high level of interest following the event.

About the Morgan Stanley Inclusive Ventures Lab
The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of startup founders, which our research shows equals over four trillion dollars in unrealized returns.

About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240913405364/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release

Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release

Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release

Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye